

Supplemental Table S2. Subgroup Analysis of End-Stage Kidney Disease in the Studies Longer than 52 Weeks

	Placebo	DPP-4 inhibitors	SGLT2 inhibitors
End-stage kidney disease			
Placebo	1		
DPP-4 inhibitors	0.97 (0.74–1.34)	1	
SGLT2 inhibitors	0.58 (0.38–0.81)	0.60 (0.34–0.91)	1

Values are expressed as median odds ratios (95% credible intervals).
DPP-4, dipeptidyl peptidase-4; SGLT2, sodium-glucose cotransporter 2.